Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire.
The monolonal antibody B2C10 reacts with galectin-3, a 30 kDa protein. Galectin-3 is a member of the galectin family. The protein is compose of three domains: a small amino-terminal domain, a carboxyl-terminal carbohydrate recognition domain (CRD) and amino-terminal domain containing repeating elements. Galectin-3 is normally distributed in epithelia of many organs and various inflammatory cells, including macrophages, as well as dendritic cells and Kupffer cells. The expression of this lectin is up-regulated during inflammation, cell proliferation, cell differentiation and through trans-activation by viral proteins. The expression is also affected by neoplastic transformation: up-regulated in certain types of lymphomas and thyroid carcinoma, while down-regulated in other types of malignancies, such as colon, breast, ovarian and uterine carcinomas.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: 35 kDa lectin; advanced glycation end-product receptor 3; Carbohydrate-binding protein 35; CBP 35; epsilon BP; Gal-3; Galactose-specific lectin 3; Galactoside-binding protein; GALBP; Galectin-3; IgE binding protein; IgE-binding protein; L-31; Laminin-binding protein; lectin galactoside-binding soluble 3 protein; Lectin L-29; lectin, galactose binding, soluble 3; lectin, galactoside-binding, soluble, 3; MAC-2 antigen
Gene Aliases: AGE-R3; CBP30; CBP35; gal-3; GAL3; GALBP; GALIG; L-34; L31; LGALS2; LGALS3; MAC2